| Formulary Amendments |
| Last updated: 9th July 2024 |
| Chapter |
Change |
Traffic light
status |
Reason for change |
| 06.01 |
Amendment - updated link for "Medication Management for Type 2 Diabetes in Adults Guidelines" |
Not applicable |
NENC Medicines Subcommittee |
| 01.06.04 |
Amendment - Specified lactulose oral solution only |
 |
NENC Medicines Subcommittee |
| 01.09.02 |
Amendment - Changed RAG rating for colesevalam from GREEN to GREEN PLUS |
 |
NENC Medicines Subcommittee |
| 03.09.01 |
Addition - Codeine Linctus for cough suppression in palliative care patients unable to take tablets |
|
NENC Medicines Subcommittee |
| 04.02.02 |
Amendment - removal of NTAG guidance and now referencing NICE guidance |
Not applicable |
NICE CG178 |
| 04.08.01 |
Amendment - Addition of strengths of phenobarbitol oral solution to specify use of unlicensed alcohol free oral solution in all children |
|
NENC Medicines Subcommittee |
| 04.10.02 |
Amendment - Changed RAG rating for buproprion in resistent depression from RED to GREEN PLUS |
|
NENC Medicines Subcommittee |
| 06.01.06 |
Amendment - Alignment of flash blood glucose monitoring systems with updated NTAG postion statement |
Not applicable |
NTAG & NENC Medicines Subcommittee |
| 06.01.06 |
Addition - Dexcom ONE+ and Freestyle Libre 2 Plus added as options to blood glucose monitoring section and updated link ot NENC continuous glucose monitoring position statement |
|
NENC Medicines Subcommittee |
| 08.01.02 |
Amendment - Changed RAG rating for mitomycin 0.04% eye drops from GREEN PLUS to RED |
 |
NENC Medicines Subcommittee |
| 08.01.05 |
Addition - Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over |
|
NICE TA950 |
| 08.01.05 |
Addition - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer |
|
NICE TA951 |
| 08.01.05 |
Addition - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations |
|
NICE TA952 |
| 08.01.05 |
Addition - Epcoritamab for treating relapsed or refracrtory diffuse large B-cell lymphoma after 2 or more systemic treatments |
|
NICE TA954 |
| 08.01.05 |
Addition - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms |
|
NICE TA957 |
| 08.01.05 |
Addition - Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis |
|
NICE TA959 |
| 08.02.02 |
Addition - Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over |
|
NICE TA949 |
| 09.08.01 |
Addition - Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease - terminated appraisal |
 |
NICE TA961 |
| 10.01.03 |
Amendment - Uploaded new hydroxychloroquine shared care protocol to replace previous regional variations |
 |
NENC Medicines Subcommittee |
| 10.02.01 |
Addition - Satralizumab for preventing relapses in neuromyelitis optics spectrum disorders - terminated appraisal |
Not applicable |
NICE TA960 |
| 11.08.08 |
Amendment - Addition of 114.3mg/1ml strength of aflibercept (Eylea) |
|
NENC Medicines Subcommittee |
| 13.05.03 |
Addition - Dupilumab for treating moderate to severe prurigo nodularis - added to non-formulary section |
Not applicable |
NICE TA955 |
| 13.05.03 |
Amendment - Uploaded new hydroxychloroquine shared care protocol to replace previous regional variations |
Not applicable |
NENC Medicines Subcommittee |
| Homepage |
Addition - MHRA Drug Safety Updates links for April, May and June 2024 |
Not applicable |
MHRA Drug Safety Updates |
